LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has issued inducement equity awards to two newly hired employees, a move ...

Savara Inc. (NASDAQ: SVRA) began the trading day with its shares slightly in the green. The company, a clinical stage biopharmaceutical firm focused on rare respiratory diseases, today announced the ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Research shows that iron-rich conditions boost Pseudomonas aeruginosa growth and biofilm formation, yet reduce virulence, complicating chronic lung infections.

LANGHORNE, PA — PANTHERx Rare Pharmacy and Savara Inc. (Nasdaq: SVRA) announced an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy under FDA review for a rare ...

INHALED therapy improved gas transfer and respiratory health in adults with autoimmune pulmonary alveolar proteinosis. Autoimmune pulmonary alveolar proteinosis is a rare lung disease in which ...

Objectives To investigate the long-term safety and efficacy of otilimab, an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody, for patients with rheumatoid arthritis (RA).

Inhaled molgramostim significantly improved lung gas exchange and quality of life among patients with autoimmune pulmonary alveolar proteinosis. Inhaled molgramostim significantly improved lung gas ...

Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and ...

Savara Inc. (NASDAQ:SVRA) is one of the best healthcare penny stocks to buy now. On September 9, Guggenheim raised its price target of the stock to $11 from $8 while reiterating a Buy rating. The ...